Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0579 • ACR Convergence 2023
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes
Liisa Hopia¹, Anna Laveskog², Dag Leonard³, Andreas Jonsen⁴, Johanna.T Gustafsson², Iva Gunnarsson⁵, Agneta Zickert⁶, Gunnel Nordmark⁷, Anders Bengtsson⁴, Leonid Padyukov⁸, Johanna Sandling³, Ann-Christine Syvänen⁹, Lars Rönnblom³, Magnus Andersson¹ and Elisabet Svenungsson⁶, ¹Department of Clinical Neuroscience, Unit of Neurology, Karolinska Institutet och Karolinska Universitetssjukhuset, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ⁸Karolinska Institutet, Solna, Sweden, ⁹Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…
Abstract Number: 0596 • ACR Convergence 2023
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks
Richard Furie¹, Cristina Arriens², Kenneth Kalunian³, Marilyn Pike⁴, Ronald van Vollenhoven⁵, Coburn Hobar⁶, Ayanbola Elegbe⁶, Samantha Pomponi⁶, Subhashis Banerjee⁶, Shalabh Singhal⁶, Thomas Wegman⁷ and Eric Morand⁸, ¹Northwell Health, Manhasset, NY, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³University of California San Diego, La Jolla, CA, ⁴MedPharm consulting, Inc., Raleigh, NC, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Beaver Falls, PA, ⁸Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. In…
Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Shivani Garg¹, Brad Astor², S. Sam Lim³, Amish Raval², Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…
Abstract Number: 0888 • ACR Convergence 2023
Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model
Helene ASNAGLI¹, Simon TESSIER¹, Martyn FOSTER², Sofie DENIES³, Eef HOEBEN⁴, Joël CROUZET¹ and Annegret VAN DER AA¹, ¹Ermium Therapeutics, Paris, France, ²Experimental Pathology Consultancy, Benfleet, United Kingdom, ³SD Analytics, Bellem, Belgium, ⁴2-Bridge, Zoersel, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…
Abstract Number: 0908 • ACR Convergence 2023
Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function
Tammy Nowling, bethany wolf, Calvin Blaschke, Richard Drake, Sandra Sanchez, Mariia Stefanenko, Mykhailo Fedoriuk, Oleg Palygin, Hongxia Bai and Jessalyn Rodgers, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE primarily afflicts women and many SLE patients develop nephritis, a serious complication of lupus. Identification of biomarkers and the pathogenic mechanisms underlying LN…
Abstract Number: 0929 • ACR Convergence 2023
Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms
Reiko Takahashi and Yoshitaka Imura, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan
Background/Purpose: SOCS1 (suppressor of cytokine signaling 1) is a suppressor molecule of the JAK/STAT pathway and has been reported to be involved in the pathogenesis…
Abstract Number: 1223 • ACR Convergence 2023
Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis
Carla Levin¹, Andrea Ontaneda², Danielle Guffey³, Peter Rycus⁴, Marc Anders², Eyal Muscal⁵ and Maria Pereira⁵, ¹Department of Pediatrics, Baylor College of Medicine, Houston, TX, ²Division of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston, TX, ³Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, ⁴Extracorporeal Life Support Organization, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystemic autoimmune disorder that can cause life-threatening complications. There is a paucity of data on the utility…
Abstract Number: 1353 • ACR Convergence 2023
Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Maria Helena Lourenco¹, Rita Torres², Santiago Rodrigues-Manica³, Vanessa Fraga⁴, Ana Catarina Abreu⁵, Roberto Costa⁶, Carolina Ochôa Matos⁷, Beatriz Mendes⁸, Beatriz Samões⁹, Inês Silva¹, Fernando Pimentel-Santos¹⁰, Manuela Costa¹, Jaime Branco¹¹ and Alexandre Sepriano¹², ¹Hospital Egas Moniz, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal, ³Hospital Egas Moniz, CHLO, Lisboa, Portugal, ⁴Hospital Garcia de Orta, Nogueira da Regedoura, Portugal, ⁵Hospital Garcia de Orta, Lisboa, Portugal, ⁶Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁷Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁰NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ¹¹CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, ¹²Leiden University Medical Centre, Portela Loures, Portugal
Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a…
Abstract Number: 1451 • ACR Convergence 2023
Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
Micaela Fredi¹, Silvia Ebe Lucia Della Pina¹, Claudia Barison¹, Chiara Orlandi¹, Marzia Tedeschi², Mai Chiara², Cecilia Nalli¹ and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²University of Brescia, Brescia, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a high degree of variability at onset, which may make SLE diagnosis challenging, with…
Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Hsin Yen Liu¹, Jiandong Su², Dennisse Bonilla², Sara Duaibes², Juan Pablo Diaz Martinez³ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…
Abstract Number: 1485 • ACR Convergence 2023
Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco² and Socorro Méndez Martínez¹, ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE…
Abstract Number: 1502 • ACR Convergence 2023
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Kanako Kojima¹, Kunihiro Ichinose¹, Toshimasa Shimizu¹, Masataka Umeda¹, Takahisa Suzuki², Yoshikazu Nakashima³, Akitomo Okada⁴, Yoshiro Horai⁵, Keita Fujikawa⁶, Toshiyuki Aramaki⁷, Taiichiro Miyashita⁸, Masako Furuyama³, Naoki Matsuoka⁹ and Atsushi Kawakami¹⁰, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ³Nagasaki Kita Hospital, Nagasaki, Japan, ⁴National Hospital Organization Nagasaki Medical Center, Omura, Japan, ⁵Sasebo City General Hospital, Sasebo, Japan, ⁶Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, ⁷Sasebo Chuo Hospital, Sasebo, Japan, ⁸Miyashita Rheumatology Clinic, Omura, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Nagasaki University, Nagasaki, Japan
Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…
Abstract Number: 1599 • ACR Convergence 2023
Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus
Mitra Maz¹, Feiyang Ma², Mehrnaz Gharaee-Kermani², Amanda Victory², Amy Hurst², Johann E. Gudjonsson² and J. Michelle Kahlenberg², ¹University of Michigan Medical School, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 2030 • ACR Convergence 2023
Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History
Kimberly DeQuattro¹, Laura Trupin², Sarah Patterson³, Stephanie Rush², Caroline Gordon⁴, Kurt Greenlund⁵, Kamil Barbour⁵, Cristina Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era², Jinoos Yazdany² and Patti Katz⁸, ¹University of Pennsylvania, Media, PA, ²University of California San Francisco, San Francisco, CA, ³University of California San Francisco, Pacifica, CA, ⁴Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Centers for Disease Control and Prevention, Atlanta, GA, ⁶National Human Genome Research Institute, Washington, DC, ⁷NIH/NHGRI, Bethesda, MD, ⁸University of California San Francisco, San Rafael, CA
Background/Purpose: Trauma exposures are associated with SLE onset and disease activity; perceived stress is also associated with greater SLE disease activity and worse patient-reported outcomes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.